VIR-3434 is under clinical development by Vir Biotechnology and currently in Phase II for Hepatitis D. According to GlobalData, Phase II drugs for Hepatitis D have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VIR-3434’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VIR-3434 is under development for the treatment of hepatitis B and D infections. The drug candidate is administered by subcutaneous or intravenous route. It is developed based on the antibody platform.
Vir Biotechnology overview
Vir Biotechnology (Vir) is a biotechnology company which carries out the development of therapeutic products to prevent and treat serious infectious diseases. It develops treatments for viral and bacterial diseases and those that induce protective and therapeutic immune responses. The company undertakes a multi-program, multi-platform approach to apply these breakthroughs. Vir primarily focuses on chronic infectious diseases including hepatitis B, tuberculosis, and HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV), and metapneumovirus (MPV); and healthcare-acquired infections. It operates in Portland, Oregon, Boston, Massachusetts, Bellinzona, Switzerland. Vir is headquartered in San Francisco, California, the US.
For a complete picture of VIR-3434’s drug-specific PTSR and LoA scores, buy the report here.